Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphate in vitro and in vivo

2016 ◽  
Vol 85 ◽  
pp. 31-38 ◽  
Author(s):  
Jennyfer Cázares-Delgadillo ◽  
Adriana Ganem-Rondero ◽  
Virginia Merino ◽  
Yogeshvar N. Kalia
Author(s):  
Graciela Lizeth Pérez-González ◽  
Luis Jesús Villarreal-Gómez ◽  
Amelia Olivas-Sarabia ◽  
Ricardo Valdez ◽  
José Manuel Cornejo-Bravo

2010 ◽  
Vol 39 (5) ◽  
pp. 387-393 ◽  
Author(s):  
Jennyfer Cázares-Delgadillo ◽  
Adriana Ganem-Rondero ◽  
David Quintanar-Guerrero ◽  
Alicia C. López-Castellano ◽  
Virginia Merino ◽  
...  

2020 ◽  
Author(s):  
Hitomi Amano ◽  
Yoshiro Kitagawa ◽  
Taichiro Muto ◽  
Akihisa Okumura ◽  
Hideyuki Iwayama

Abstract BackgroundAnaphylaxis is a severe systemic allergic reaction. Glucocorticoids rarely induce anaphylaxis. Determination of allergens includes the in vivo skin prick test (SPT) and intradermal skin test (IDST) and the in vitro basophil activation test (BAT). However, the usefulness of BAT in determining drug allergens has not been adequately studied.Case presentation A 10-year-old boy was admitted to our hospital because of fever and arthralgia for 2 weeks. He had not been treated with glucocorticoids. According to the laboratory tests and imaging studies, he was suspected to have bacterial myositis and was treated with ceftriaxone. However, his symptoms persisted for more than 2 weeks. With a suspicion of autoinflammatory arthritis, we planned methylprednisolone (mPSL) sodium succinate (MPS) during pulse therapy (30 mg/kg). Fifteen minutes after the injection of mPSL, he had wheezing and generalized wheal formation with decreased oxygenation. The administration of mPSL was discontinued because anaphylaxis was suspected. Thirty minutes after the administration of oxygen and oral olopatadine, the anaphylactic symptoms resolved. One month after discharge, SPT, IDST, and BAT were performed under the administration of oral prednisolone. The SPTs for MPS, hydrocortisone sodium succinate (HCS) and prednisolone sodium succinate (PSS) were negative. The IDST for MPS was positive. Moreover, the IDSTs for HCS and PSS were positive, whereas those for dexamethasone sodium phosphate and betamethasone sodium phosphate were negative. The BAT for MPS was negative at 1.0% and 1.9% after an incubation time of 1 hour and 24 hours, respectively, although the BAT for histamine as positive control was 60.4% and 18.3% after an incubation time of 1 hour and 24 hours, respectively. The BATs for HCS and PSS were negative. Therefore, we diagnosed as anaphylaxis secondary to the succinate ester in MPS.ConclusionsIn this case, IDST was useful for the diagnosis of MPS-induced anaphylaxis, whereas BAT was negative. This highlighted the need to choose the appropriate procedure in the diagnosis of steroid-induced anaphylaxis. The results in our patient suggested that BAT may be considered when IDST and SPT are negative. Further studies are necessary to clarify the diagnostic strategy for steroid-induced anaphylaxis.


1970 ◽  
Vol 2 (1) ◽  
pp. 56-60
Author(s):  
Nazia Zaman ◽  
Md Mesbah Uddin Talukder ◽  
Tasnuva Haque ◽  
Md Khairul Alam ◽  
Kanij Fatema

The present study was carried out to develop biodegradable intrascleral implants of Dexamethasone Sodium Phosphate and to evaluate the release pattern of the drug from the prepared implants. Intrascleral implants were prepared by using biodegradable polymer L-PLA (m.wt. 61,200 Da). Sodium chloride (NaCl), gelatin and glycerol monostearate (GMS) were used in various formulations to observe the effects of these additives on the release of Dexamethasone Sodium Phosphate from the prepared L-PLA based intrascleral implants. Five different formulations were prepared for this study and were coded as FD-1 (10%drug+L-PLA), FD-2 (20%drug+L-PLA), FD-3 (10%drug+L-PLA+5%NaCl), FD-4 (10%drug+L-PLA +5%Gelatin) and FD-5 (10%drug+L-PLA+10% GMS). Discs were prepared and made into appropriate shape before submerging into the buffer solution of pH 7.4 in different vials. The in vitro release profile of Dexamethasone Sodium Phosphate from the implants showed a biphasic release pattern with an initial burst followed by a diffusive phase. It was observed that FD-1 and FD-2 showed 19.63% and 29.87% release on the first day and 24.22% and 38.5% release respectively at day 30. The drug loading of FD-1 and FD-2 was 10% and 20% respectively. Among FD-3, FD-4 and FD-5; FD-3 showed highest release (32.1%) at day 30 in which 5% NaCl was used. FD-4 showed 27.45% release at day 30 where gelatin, a hydrophilic agent was used and FD-5 containing GMS, a lipid material, was found to be most retarding (19.22% at day 30). The results of the dissolution study provide an idea that L-PLA may be successfully used for the preparation of biodegradable intrascleral implant of Dexamethasone Sodium Phosphate. Key words: Dexamethasone Sodium Phosphate; Bioidegradable polymer; Intrascleral implants. DOI: 10.3329/sjps.v2i1.5817Stamford Journal of Pharmaceutical Sciences Vol.2(1) 2009: 56-60


2018 ◽  
Vol 32 (2) ◽  
pp. 102-110 ◽  
Author(s):  
Shodeinde A. Coker ◽  
Zbigniew M. Szczepiorkowski ◽  
Alan H. Siegel ◽  
Antonio Ferrari ◽  
Giovanni Mambrini ◽  
...  

ChemBioChem ◽  
2015 ◽  
Vol 16 (9) ◽  
pp. 1323-1332 ◽  
Author(s):  
Werner E. G. Müller ◽  
Meik Neufurth ◽  
Jian Huang ◽  
Kui Wang ◽  
Qingling Feng ◽  
...  

Pharmaceutics ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 354
Author(s):  
Maria S. Synaridou ◽  
Eleftherios G. Andriotis ◽  
Constantinos K. Zacharis ◽  
Dimitrios G. Fatouros ◽  
Catherine K. Markopoulou

Undesirable taste has always been a key issue for oral dosage forms. The aim of the present study was to co-formulate dexamethasone sodium phosphate (DSP), in common pediatric oral forms, using sweet preserves and/or different types of chocolate as excipients. An array of different kinds of chocolate were co-formulated with DSP and were further characterized by means of dynamic light scattering (DLS), x-ray diffraction (XRD), differential scanning calorimetry (DSC) and Fourier-transform infrared (FT-IR) spectroscopy. For the assay of active pharmaceutical ingredient (API), the chocolate samples were pre-treated by means of liquid extraction and analyzed using an high-performance liquid chromatographic (HPLC) method with a strong anion exchange column and a phosphate buffer (17 mM, pH = 3)/acetonitrile, 50:50 v/v as mobile phase. The developed chromatographic method was validated based on the International Conference on Harmonization (ICH) guidelines (%Mean Recovery = 99.4% and %Relative Standard Deviation, RSD = 0.43%). Furthermore, dissolution and in vitro digestion tests of chocolate formulations were evaluated. The DSP was found to be stable for at least 1 year in prepared preparations.


Sign in / Sign up

Export Citation Format

Share Document